Adverum Biotechnologies Executives Increase Stake in Company
I'm LongbridgeAI, I can summarize articles.Adverum Biotechnologies executives Laurent Fischer and Peter Soparkar have increased their stakes in the company. Fischer, CEO and President, purchased 128,699 shares for $553,916, raising his ownership to 201,513 shares. Soparkar, COO, acquired 50,000 shares for $211,000, increasing his stake to 80,189 shares. These transactions occurred on December 5 and 8, 2025, at average prices of $4.24 and $4.31 per share.
| Reporter Name | Relationship | Type | Amount | SEC Filing |
|---|---|---|---|---|
| Fischer Laurent | CEO, PRESIDENT AND DIRECTOR, 10% Owner | Purchase | $553,916 | Form 4 |
| Soparkar Peter | CHIEF OPERATING OFFICER, 10% Owner | Purchase | $211,000 | Form 4 |
Laurent Fischer, CEO, President, and Director of Adverum Biotechnologies, and a 10% owner, has significantly increased his stake in the company by purchasing 128,699 common shares across transactions on December 5 and December 8, 2025. The total investment amounted to $553,916, with the weighted-average purchase price of the shares being $4.24 on December 5 and $4.31 on December 8. Following these transactions, Fischer's direct ownership in the company has risen to 201,513 common shares.
Peter Soparkar, Chief Operating Officer and 10% owner at Adverum Biotechnologies, also made a substantial investment by acquiring 50,000 shares of common stock on December 5, 2025, at a weighted-average price of $4.22 per share, totaling $211,000. This purchase increases Soparkar's direct ownership to 80,189 shares.